David J. Elliot
About
David J. Elliot is a scholar working on Pharmacology, Oncology and Molecular Biology.
According to data from OpenAlex, David J. Elliot has authored 77 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pharmacology, 26 papers in Oncology and 15 papers in Molecular Biology. Recurrent topics in David J. Elliot's work include Pharmacogenetics and Drug Metabolism (27 papers), Drug Transport and Resistance Mechanisms (21 papers) and Organometallic Complex Synthesis and Catalysis (9 papers). David J. Elliot is often cited by papers focused on Pharmacogenetics and Drug Metabolism (27 papers), Drug Transport and Resistance Mechanisms (21 papers) and Organometallic Complex Synthesis and Catalysis (9 papers). David J. Elliot collaborates with scholars based in Australia, United Kingdom and United States. David J. Elliot's co-authors include John O. Miners, Peter I. Mackenzie, Benjamin C. Lewis, Kathleen Knights, Verawan Uchaipichat, Andrew Rowland, Kushari Bowalgaha, J. Andrew Williams, Arduino A. Mangoni and Leanne K. Winner and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biochemistry and Langmuir.
In The Last Decade
David J. Elliot
73 papers receiving 2.2k citations
Peers
David J. Elliot
Liang‐Shang Gan United States
Tristan S. Maurer United States
David R. Jones United States
Geert Mannens Belgium
J. Gerry Kenna United Kingdom
Shengying Qin China
Guoxin Hu China
Hannah M. Jones United States
Matthew D. Troutman United States
John M. Strong United States
Citations per year, relative to David J. Elliot David J. Elliot (= 1×)
peers
Liang‐Shang Gan
Countries citing papers authored by David J. Elliot
Since
Specialization
Citations
This map shows the geographic impact of David J. Elliot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. Elliot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. Elliot more than expected).
Fields of papers citing papers by David J. Elliot
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by David J. Elliot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. Elliot. The network helps show where David J. Elliot may publish in the future.
Co-authorship network of co-authors of David J. Elliot
This figure shows the co-authorship network connecting the top 25 collaborators of David J. Elliot. A scholar is included among the top collaborators of David J. Elliot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. Elliot. David J. Elliot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Hulin, Julie-Ann, Sara Tommasi, David J. Elliot, & Arduino A. Mangoni. (2019). Small molecule inhibition of DDAH1 significantly attenuates triple negative breast cancer cell vasculogenic mimicry in vitro. Biomedicine & Pharmacotherapy. 111. 602–612.
2.
Hulin, Julie-Ann, Sara Tommasi, David J. Elliot, et al.. (2017). MiR-193b regulates breast cancer cell migration and vasculogenic mimicry by targeting dimethylarginine dimethylaminohydrolase 1. Scientific Reports. 7(1). 13996–13996.
3.
Miners, John O., Kushari Bowalgaha, David J. Elliot, Paweł Baranczewski, & Kathleen Knights. (2011). Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation. Drug Metabolism and Disposition. 39(4). 644–652.
4.
Birkett, Donald, et al.. (2011). Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes. Drug Metabolism and Disposition. 39(9). 1711–1717.
5.
Raungrut, Pritsana, Verawan Uchaipichat, David J. Elliot, et al.. (2010). In Vitro–In Vivo Extrapolation Predicts Drug–Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans. Journal of Pharmacology and Experimental Therapeutics. 334(2). 609–618.
6.
Elliot, David J., et al.. (2010). Effect of Albumin on Human Cytochromes P450 Kinetics: Extrapolation of in Vivo Clearance from in Vitro Data. 32(1). 246–249.
7.
Mackenzie, Peter I., David J. Elliot, Nuy Chau, et al.. (2010). The Novel UDP Glycosyltransferase 3A2: Cloning, Catalytic Properties, and Tissue Distribution. Molecular Pharmacology. 79(3). 472–478.
8.
Polasek, Thomas M., et al.. (2009). In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. European Journal of Clinical Pharmacology. 66(3). 275–283.
9.
Knights, Kathleen, Leanne K. Winner, David J. Elliot, Kushari Bowalgaha, & John O. Miners. (2009). Aldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP‐glucuronosyltransferases: Inhibition by NSAIDs. British Journal of Clinical Pharmacology. 68(3). 402–412.
10.
Knights, Kathleen, et al.. (2008). In vitro characterisation of human renal and hepatic frusemide glucuronidation and identification of the UDP-glucuronosyltransferase enzymes involved in this pathway. Biochemical Pharmacology. 76(2). 249–257.
11.
Elliot, David J.. (2007). Puerto Rico: A Site of Critical Performative Pedagogy.. 6(1). 1–24.
12.
Elliot, David J., et al.. (2007). Influence of mutations associated with Gilbert and Crigler–Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenetics and Genomics. 17(12). 1017–1029.
13.
Rowland, Andrew, et al.. (2007). Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation. Journal of Pharmacology and Experimental Therapeutics. 321(1). 137–147.
14.
Lewis, Benjamin C., Peter I. Mackenzie, David J. Elliot, et al.. (2006). Amino terminal domains of human UDP-glucuronosyltransferases (UGT) 2B7 and 2B15 associated with substrate selectivity and autoactivation. Biochemical Pharmacology. 73(9). 1463–1473.
15.
Uchaipichat, Verawan, Leanne K. Winner, Peter I. Mackenzie, et al.. (2006). Quantitative prediction ofin vivoinhibitory interactions involving glucuronidated drugs fromin vitrodata: the effect of fluconazole on zidovudine glucuronidation. British Journal of Clinical Pharmacology. 61(4). 427–439.
16.
Rowland, Andrew, David J. Elliot, J. Andrew Williams, et al.. (2006). IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION. Drug Metabolism and Disposition. 34(6). 1055–1062.
17.
Bowalgaha, Kushari, David J. Elliot, Peter I. Mackenzie, et al.. (2005). S‐Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP‐glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. British Journal of Clinical Pharmacology. 60(4). 423–433.
18.
Johnson, Daniel L., Benjamin C. Lewis, David J. Elliot, John O. Miners, & Lisandra L. Martin. (2005). Electrochemical characterisation of the human cytochrome P450 CYP2C9. Biochemical Pharmacology. 69(10). 1533–1541.
19.
Uchaipichat, Verawan, Peter I. Mackenzie, David J. Elliot, & John O. Miners. (2005). SELECTIVITY OF SUBSTRATE (TRIFLUOPERAZINE) AND INHIBITOR (AMITRIPTYLINE, ANDROSTERONE, CANRENOIC ACID, HECOGENIN, PHENYLBUTAZONE, QUINIDINE, QUININE, AND SULFINPYRAZONE) “PROBES” FOR HUMAN UDP-GLUCURONOSYLTRANSFERASES. Drug Metabolism and Disposition. 34(3). 449–456.
20.
Elliot, David J., C.J. Levy, Richard J. Puddephatt, et al.. (1990). A bridged cobaltaborane complex: the first structural characterization of a transition metal-BH2 bond. Inorganic Chemistry. 29(25). 5014–5015.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Liang‐Shang Gan Breakdown of academic impact, for papers by Tristan S. Maurer Breakdown of academic impact, for papers by David R. Jones Breakdown of academic impact, for papers by Geert Mannens Breakdown of academic impact, for papers by J. Gerry Kenna Breakdown of academic impact, for papers by Shengying Qin Breakdown of academic impact, for papers by Guoxin Hu Breakdown of academic impact, for papers by Hannah M. Jones Breakdown of academic impact, for papers by Matthew D. Troutman Breakdown of academic impact, for papers by John M. Strong